{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.60","upperLimit":"11.86","value":"9.56"},{"groupId":"OG001","lowerLimit":"4.99","upperLimit":"7.75","value":"5.95"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"156"}],"units":"Participants"}],"description":"Overall survival was measured from the date of randomization to death from any cause, subjects not known to have died by the last follow-up were censored on the date they were last known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with CPX-351. The number of inductions and consolidations a subject received depended on response.","id":"OG000","title":"Arm A (CPX-351)"},{"description":"Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with cytarabine and daunorubicin given as a 7 + 3, or 5 days of continuous infusion of cytarabine and 2 days of daunorubicin (5+2, second induction, consolidation courses) therapy. The number of inductions and consolidations a subject received depended on response.","id":"OG001","title":"Arm B (7+3)"}],"paramType":"MEDIAN","populationDescription":"Intent-to-Treat (ITT) Population: All participants randomized in the study.","reportingStatus":"POSTED","timeFrame":"From the date of randomization to death from any cause","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"months"}